Egypt Pharmaceuticals and Healthcare Report Q3 2013

Date: June 19, 2013
Pages: 111
Price:
US$ 1,295.00
Publisher: Business Monitor International
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E868351A17DEN
Leaflet:

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: While BMI’s core view for Egypt is that it will eventually emerge from its political turmoil as a stronger economy with a greater emphasis on healthcare, there are obvious downside risks to this view. The biggest threats to the country’s pharmaceuticals and healthcare industry are the drug pricing regime - which is disadvantaging local production with unprofitable margins - the political uncertainty and the loss of foreign investment and tourism, which bodes poorly for its macroeconomic growth.

Headline Expenditure Projections

Pharmaceuticals: EGP12.83bn (US$2.11bn) in 2012 to EGP14.45bn (US$2.01bn) in 2013; +12.6% in local currency terms and -5.0% in US dollar terms. Local currency forecast largely in line with Q213.

Healthcare: EGP74.16bn (US$12.22bn) in 2012 to EGP85.35bn (US$11.85bn) in 2013; +15.1% in local currency terms and -3.0% in US dollar terms. Local currency slightly higher in relation to Q213, on account of new historical data.
Executive Summary
SWOT Analysis
Egypt Pharmaceuticals & Healthcare Industry SWOT
Egypt Political SWOT
Egypt Economic SWOT
Egypt Business Environment SWOT
Pharmaceuticals Risk/Reward Ratings
Egypt’s Risk/Reward Rating
Rewards
Risks
Egypt – Market Summary
Regulatory Regime
Lacking Drug Registration Transparency
Regulatory Developments
Regional Harmonisation
Intellectual Property Developments
IP Shortcomings
Counterfeit Medicines
Free Trade Agreements
Pricing Regime
Reimbursement Regime
  Table: Essential Drugs List
Industry Developments
Epidemiology
Communicable Diseases
Non-Communicable Disease
Healthcare Sector
Private Healthcare Sector
Healthcare Staff
Healthcare Financing
Healthcare Insurance
Research & Development
Clinical Trials
Industry Forecast Scenario
Pharmaceutical Market Forecast
  Table: Egypt Pharmaceutical Sales, Historical Data and Forecasts, 2009-2017
Healthcare Market Forecast
  Table: Egypt Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017
  Table: Egypt Government Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017
  Table: Egypt Private Healthcare Expenditure Trends, Historical Data and Forecasts, 2009-2017
Key Growth Factors – Macroeconomic
Egypt - GDP By eExpenditure, US$ Terms Breakdown, 2009-2017
Prescription Drug Market Forecast
  Table: Egypt Prescription Drug Market Indicators, Historical Data and Forecasts, 2009-2017
Patented Drug Market Forecast
  Table: Egypt Patented Drug Market Indicators, Historical Data and Forecasts, 2009-2017
Generic Drug Market Forecast
  Table: Egypt Generics Drug Market Indicators, Historical Data and Forecasts, 2009-2017
OTC Medicine Market Forecast
  Table: Egypt Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts, 2009-2017
Pharmaceuticals Trade Forecast
  Table: Egypt Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017
  Table: Egypt Pharmaceutical Trade Data And Forecasts (EGPmn), 2009-2017
Other Healthcare Data
Key Risks To BMI’s Forecasts
Competitive Landscape
Pharmaceutical Industry
  Table: HOLDIPHARMA’s Affiliated Companies, 2012
  Table: HOLDIPHARMA’s Joint Ventures, 2012
Domestic Pharmaceuticals Sector
  Table: HOLDIPHARMA’s Financial Indicators, FY 2006/2007-FY2010/2011 (EGPmn)
  Table: HOLDIPHARMA’s Net Operating Revenue by Affiliate, FY 2010/2011 (EGPmn)
  Table: Wholly Or Partially Owned Egyptian Pharmaceutical And Medical Device Companies By Parent Group
Foreign Pharmaceuticals Sector
Industry Developments
Pharmaceutical Wholesale
Pharmaceutical Retail
Herbal And OTC Medicine
Company Profiles
Domestic Companies
Egyptian International Pharmaceutical Industries Co (EIPICO)
South Egyptian Drug Industries (SEDICO)
Medical Union Pharmaceuticals (MUP)
Amoun Pharmaceutical Company (APC)
VASCERA
Misr Pharmaceuticals
Multinational Companies
GlaxoSmithKline (GSK)
Sanofi
Pfizer
Novartis
Merck & Co
AstraZeneca
Demographic Outlook
  Table: Population By Age Group, 1990-2020 (‘000)
  Table: Population By Age Group, 1990-2020 (% of total)
  Table: Key Population Ratios, 1990-2020
  Table: Rural/Urban Population Split, 1990-2020
Glossary
BMI Methodology
How We Generate Our Pharmaceuticals Industry Forecasts
Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceuticals Business Environment Indicators
Weighting
  Table: Weighting Of Components
Sources
Egypt Pharmaceuticals and Healthcare Report Q1 2014 US$ 1,295.00 Dec, 2013 · 130 pages
Egypt Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00 Mar, 2014 · 124 pages
OTC Healthcare in Egypt to 2014 US$ 495.00 Jul, 2010 · 170 pages
Algeria Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00 Feb, 2014 · 105 pages
Belgium Pharmaceuticals and Healthcare Report Q4 2013 US$ 1,295.00 Sep, 2013 · 107 pages

Ask Your Question

Egypt Pharmaceuticals and Healthcare Report Q3 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: